# Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

> **NCT07482605** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangmen Central Hospital** · enrollment: 63 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)
- Malignant Pleural Effusions (Mpe)- Pleurodesis

## Interventions

- **DRUG:** Furmonertinib
- **RADIATION:** Thoracic Radiotherapy (TRT)

## Key facts

- **NCT ID:** NCT07482605
- **Lead sponsor:** Jiangmen Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-10-30
- **Final completion:** 2028-01-01
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07482605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07482605, "Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07482605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*